Explore

Recent news and media from the Citizen Stash squad.

Experion Holdings Ltd. Signs LOI with the Société Québécoise du Cannabis (SQDC) to Supply Cannabis Products for Distribution and Sale in the Province

VANCOUVER, BC and MONTREAL, QC, September 10, 2019 (FSCwire) Experion Holdings Ltd. (TSXV: EXP) (OTCQB:EXPFF) (FRANKFURT:MB31), formerly Viridium Pacific Group Ltd today announced that its wholly-owned subsidiary Experion Biotechnologies Inc. (“Experion or “the Company’’), a Health Canada licensed cultivator and processor of Cannabis has signed a Letter of Intent (“LOI”) with the Société québécoise du cannabis (“SQDC”) Québec’s sole legal retailer of recreational cannabis, to supply Adult-Use cannabis products to the SQDC for distribution and sale in the Province of Québec.

 

Mr. Jay Garnett, Chief Executive Officer, commented “We are pleased to work with the SQDC and deliver products that will meet the demand of its customers. This agreement further solidifies Experion’s position in Canada’s legal adult use cannabis marketplace expanding our distribution beyond British Columbia and Saskatchewan”

 

Under the terms of the LOI, Experion through its wholly owned Kanabé Goods Co. (‘’ Kanabé”), an adult-use health & wellness brand, will supply products in the form of THC and CBD oil capsules. Shipments to Québec are scheduled to start in December and continue throughout 2020.

 

Ms. Krystal Laferriere, Experion’s Cannabis Wellness Expert and Co-Founder of Kanabé Goods Co. who had created the product line to soothe side-effects and other ailments suffered as a result of her Crohn’s Disease, commented, “Part of Experion’s growth strategy is focused on establishing a strong national footprint and building our brand presence. It is a great accomplishment to have Québec as Kanabé’s entry point into the domestic market. Our capsules will serve those looking for a micro-dose, option made from our full spectrum oil. Kanabé will also roll out more products such as oral sprays. We are proud to have this opportunity to partner with Québec and the SDQC to help ensure Canadians have access to a reliable supply of adult-use cannabis products”

 

About Kanabe Goods Co.

Kanabé Goods Co. www.kanabe.ca creates therapeutic health and wellness products containing cannabis and has over 50 formulations in its portfolio including topical salves, lotions, oils as well as edible oils and capsules. Kanabé products were developed to target and soothe various aliments by combining cannabinoids, terpenes and aromatherapy with a focus on discretion and ease of use by developing products that are already found in consumers everyday life. Kanabé is an adult-use, over-the-counter health & wellness brand ingraining into daily actions and rituals for comfort and solutions to acute problems ranging from sore muscles, to sleep and skin issues.

 

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

Experion trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “EXP” on the OTCQB Venture under the symbol “EXPFF” and on the Frankfurt Stock Exchange under the symbol “MB31” For further information, please visit the Company’s website www.experionwellness.com or join our Global Investor Forum on 8020 http://connects.company/ExperionEXP where you can read all press releases or contact Investor Relations, Judy-Ann Pottinger, Phone: 604- 617-5290 Email: judy-ann@experionwellness.com

 

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct. Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

 

__________________

 

Experion Holdings Ltd. Signature d’une lettre d’intention avec la Société québécoise du Cannabis (SQDC) pour la distribution et la vente de produits de cannabis dans la province

 

VANCOUVER, BC et MONTRÉAL, QC, 10 septembre, 2019 (FSCwire) Experion Holdings Ltd. (TSXV: EXP) (OTCQB:EXPFF) (FRANKFURT:MB31), anciennement Viridium Pacific Group Ltd a annoncé aujourd’hui que sa filiale en propriété exclusive Experion Biotechnologies Inc. (« Experion » ou « la compagnie »), un cultivateur et transformateur de cannabis autorisé par Santé Canada, a signé une lettre d’intention(« LI ») avec la Société québécoise du cannabis (“SQDC”) le seul détaillant légal de cannabis récréatif au Québec, pour lui fournir des produits de cannabis pour les adultes pour une distribution et une vente dans la province de Québec.

 

M. Jay Garnett, chef de la direction, a déclaré: « Nous sommes heureux de travailler avec la SQDC et de livrer des produits qui répondront à la demande de nos clients. Cet accord renforce la position d’Experion sur le marché canadien de l’usage légal du cannabis pour les adultes et étend notre distribution au-delà de la Colombie-Britannique et de la Saskatchewan ».

 

Aux termes de la lettre d’intention, Experion, par l’entremise de Kanabé Goods Co. (« Kanabé »), une marque de produits de santé et de bien-être pour adultes, fournira des produits sous forme de capsules d’huile de THC et de CBD. Les expéditions vers le Québec devraient débuter en décembre et se poursuivre tout au long de l’année 2020.

 

Mme Krystal Laferrière, experte chez Experion Cannabis Wellness et co-fondatrice de Kanabé Goods Co, a commenté: “Une partie de la stratégie de croissance d’Experion est axée sur l’établissement d’une forte empreinte nationale et le renforcement de notre présence de marque. C’est une grande réalisation que d’avoir le Québec comme point d’entrée de Kanabé sur le marché intérieur. Nos capsules serviront à ceux qui recherchent une microdose, option faite à partir de notre huile à spectre complet. Kanabé lancera également d’autres produits comme les vaporisateurs oraux. Nous sommes fiers d’avoir l’occasion de travailler en partenariat avec le Québec et la SQDC pour aider à assurer aux Canadiens un approvisionnement fiable en produits de cannabis destinés aux adultes”.

 

À propos de Kanabé Goods Co.

Kanabé Goods Co. www.kanabe.ca crée des produits thérapeutiques de santé et de bien-être contenant du cannabis et compte plus de 50 formulations dans son inventaire, y compris des pommades topiques, des lotions, des huiles ainsi que des huiles et capsules comestibles. Les produits Kanabé ont été développés pour cibler et apaiser différents aliments en combinant les cannabinoïdes, les terpènes et l’aromathérapie avec un souci de discrétion et de facilité d’utilisation en développant des produits déjà présents dans la vie quotidienne des consommateurs. Kanabé est une marque de santé et de bien-être en vente libre pour les adultes et qui s’insère dans les actions et les rituels quotidiens pour le confort et les solutions aux problèmes aigus allant des douleurs musculaires aux problèmes de sommeil et de la peau.

 

À propos de Experion Holdings Ltd.

Experion Holdings Ltd est la société mère d’Experion Biotechnologies Inc, un cultivateur et transformateur de cannabis autorisé par Santé Canada, dont le siège social est situé à Mission, en Colombie-Britannique, et de EFX Laboratories Inc, une société de production de produits médicaux et de recherche clinique située à Calgary, en Alberta.

Experion Holdings Ltd investit dans une gamme de produits destinés à répondre à un large éventail de besoins des consommateurs, notamment des produits médicaux, des produits pour adultes et des produits de bien-être et thérapeutiques.

 

Experion se transige à la Bourse de croissance TSX à titre d’émetteur de niveau 1 sous le symbole « EXP » sur la Bourse de croissance OTCQB sous le symbole « EXPFF » et à la Bourse de Francfort sous le symbole « MB31 ». Pour plus d’informations, veuillez visiter le site Web de la Société www.experionwellness.com ou rejoindre notre forum d’investisseur global au 8020 http://connects.company/ExperionEXP où vous pouvez lire tous les communiqués de presse ou contacter les relationnistes pour les investisseurs, Judy-Ann Pottinger, tél.: 604 617-5290 courriel judy-ann@experionwellness.com

 

Divulgation
Le présent communiqué de presse contient de l’information prospective au sens des lois canadiennes sur les valeurs mobilières. Bien que la Société estime que cette information est raisonnable, elle ne peut donner aucune assurance que ces attentes se révéleront exactes. L’information prospective se reconnaît habituellement à l’emploi de mots tels que: croire, s’attendre à, prévoir, avoir l’intention de, estimer, prévoir, postuler et d’autres expressions semblables, ou sont ceux qui, par leur nature même, renvoient à des événements futurs. La Société met en garde les investisseurs contre le fait que toute information prospective fournie par la Société ne garantit pas les résultats ou le rendement futur et que les résultats réels peuvent différer sensiblement de ceux qui figurent dans l’information prospective en raison de divers facteurs, notamment la situation des marchés financiers des titres de participation de la Société, la volatilité récente des marchés, la capacité de la Société à mobiliser les capitaux nécessaires ou à être pleinement en mesure de réaliser ses stratégies commerciales, les risques identifiés dans l’énoncé déposé et les autres risques et facteurs dont la Société ignore pour le moment, mais non exclusivement: la conjoncture actuelle sur les marchés des actions de la Société, la récente instabilité des marchés, l’incapacité de la Société d’obtenir les capitaux dont elle a besoin et d’être en mesure d’adopter sa stratégie d’affaires, et les risques identifiés dans la Déclaration de changement de l’information financière. Le lecteur est prié de se reporter à la déclaration de changement à l’inscription datée du 25 septembre 2017 ou au rapport de gestion annuel et intermédiaire le plus récent pour une analyse plus complète de ces facteurs de risque et de leurs effets potentiels, dont des exemplaires sont disponibles sur la page de la Société sur SEDAR www.sedar.com.

, , , , , , , , , , , , , , , , , , , , , , , , ,

Experion’s Brand, Kanabé Goods Co., Well Positioned to Take Advantage of New Health Canada Regulations

VANCOUVER, British Columbia, June 21, 2019 (FSCwire) Experion Holdings Ltd. (“Experion” or the “Company”) (TSXV: EXP) (OTCQB:EXPFF), formerly Viridium Pacific Group Ltd., is pleased to provide an update on the Company’s brands positioned to take advantage of  Health Canada’s final regulations for Value-Add Products (VAP’s) such as cannabis topicals, edibles and extracts as well as Health Canada’s proposal to create a new category ‘’Cannabis Health Products’’ for therapeutic treatment of minor ailments like sleeplessness or sore muscles or for use in pets, paving the way for large new untapped market.

Mr. Jay Garnett, Chief Executive Officer commented “Experion is in continued development of our wellness-centric brand Kanabé Goods Co. www.kanabe.ca for the launch of value-add products (VAP’s). There are currently 50 plus existing formulations which we have the ability to produce in our facility and we are also working with key strategic partners for large scale commercial roll-out. These health and wellness products such as non-intoxicating topicals and micro-dosed oils are an entry point for new consumers, broadening the market potential.  The Experion management team has decades of experience in consumer-packaged goods and is well positioned to be a first mover in this category which in turn will enable Experion to stand firm in our commitment of unlocking value for our shareholders”

The VAP’s regulations come into force October 17, 2019 with product availability earliest December 16th, 2019. Furthermore, Health Canada’s proposal for Cannabis Health Products opens the door for a bigger opportunity. The proposal looks to treat health and wellness products with cannabis, similar to Natural Health Products which allows the product to make health claims based on evidence but without the oversight of a practitioner.

Mr. Garnett further commented “A Kanabé topical balm that is non-intoxicating, for example, could potentially be sold via pharmacies or online without the restrictions to have a medical cannabis prescription or buy through a licensed cannabis retailer. The accessibility to purchase is much easier on the consumer, as well as the use of the product much clearer. This proposal further aligns to our educational and public outreach efforts from our Cannabis Wellness Expert and Co-Founder of Kanabé, Krystal Laferriere, who had created the product line to soothe side-effects and other ailments suffered as a result of her Crohn’s Disease.”

Health Canada is asking the public to submit feedback on this new category via consultation paper until September 3rd.

https://www.canada.ca/en/health-canada/programs/consultation-potential-market-cannabis.html

Health Canada Final Regulations for Value-Add Products

https://www.canada.ca/en/health-canada/news/2019/06/health-canada-finalizes-regulations-for-the-production-and-sale-of-edible-cannabis-cannabis-extracts-and-cannabis-topicals.html

 

About Kanabe Goods Co

Kanabé Goods Co. www.kanabe.ca creates therapeutic health and wellness products containing cannabis and has over 50 formulations in its portfolio including topical salves, lotions, oils as well as edible oils and capsules. Kanabé products were developed to target and soothe various aliments by combining cannabinoids, terpenes and aromatherapy with a focus on discretion and ease of use by developing products that are already found in consumers everyday life. Kanabé is an adult-use, over-the-counter health & wellness brand ingraining into daily actions and rituals for comfort and solutions to acute problems ranging from sore muscles, to sleep and skin issues.

About Experion Holdings Ltd.

Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.

Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including Medical, Adult-use, and Wellness and Therapeutic products.

 

For further information, please visit the Company’s website www.experionwellness.com or contact:

 

Experion Holdings Ltd

Judy-Ann Pottinger, Investor Relations

Tel: (604) 617-5290

judy-ann@experionwellness.com

 

We invite all investors and other interested parties to join the Experion Holdings portal on 8020 Connect. Join here:  http://connects.company/Experion

 

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

, , , , , , , , , , ,

Viridium Reports Year End Results, Provides Corporate Update

March 18, 2019: Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to provide shareholders with the year end financials and a corporate update.

Year End

Viridium has now filed the year end consolidated financial statements and management discussion and analysis for the year ending November 30, 2018 on SEDAR.

Company Updates

Viridium and its wholly owned subsidiary, Experion Biotecnologies (“Experion”), a licensed cultivation and processor company under the Cannabis Act, have progressed on many fronts over the last six months. After receiving its transitional license from the ACMPR to the Cannabis Act last October, the Company focused on sales, product and brand development. On the wholesale front, Experion has supplied both cannabis flower and starting materials to over 7 licensed cultivators throughout Canada generating over $1 Million in sales since September 2018. These relationships continue to foster into strategic partnerships and potential supply agreements.

In early December 2018 and January 2019, Experion launched its first adult use cannabis brand, Citizen Stash, during the O’Cannabis Expo and Lift & Co Conference in Vancouver. Citizen Stash cannabis products are hand cultivated in Experion’s indoor facility to high standards to ensure exceptional user experience.  Experion signed a supply agreement with the BC Liquor Distribution branch to supply the province of British Columbia, followed with its first shipment shortly after. Our Citizen Stash products can now be found online and at stores.  Experion also signed an agreement with Open Fields Distribution in February to supply the province of Saskatchewan, with a shipment scheduled in the next couple of weeks. The first retail strain under Citizen Stash offered for both provinces is the Lemon Zkittle, a 60% sativa hybrid with mid to high THC, offering the user a relaxing and consistent quality effect.

Internationally, Viridium has also entered the tender process in December 2018, with the opportunity to become one of the first licensed medical cannabis companies in Germany with partner INOPHA Pharma. An indoor GMP facility capable of producing 3,000 KG per year designed by the Viridium team, including all the support processes and procedures, was submitted as part of the tender documents. Should the tender application become successful, Viridium would continue to support the implementation and construction of the facility and become an equity partner in the licensed joint venture. Regardless if the tender is successful or not, INOPHA and Viridium will continue with an import and export relationship for medical cannabis throughout Germany.

Corporately, Viridium completed the Amalgamation of EFX Laboratories in February 2019. The Amalgamation is consistent with Viridium’s stated goal of producing a strong portfolio of cannabis brands and products for the Canadian medical, wellness, and export markets and the financial and strategic benefits of the Amalgamation are uniquely compelling to shareholders of both Viridium and EFX. The Amalgamation provides a strong go-forward strategy that creates a long-term sustainable growth company focused on the “3rd wave” of investment which includes cannabis biotech applications in the retail consumer product market.

The Amalgamation enables the acceleration of completing Viridium’s and EFX’s business initiatives in the next 24 to 36 months given the strong combined balance sheet with more than $10 million cash on hand and debt free. Viridium, as combined with EFX, is now vertically integrated from seed to value added product, and has all of the Health Canada Licences it requires to execute its business strategy.

Recently, Viridium graduated from Tier 2 to Tier 1 on the TSX Venture Exchange on February 25, 2019.

About Viridium 

Viridium Pacific Group Ltd. is the parent company of Experion Biotechologies Inc., a Health Canada licensed cultivation and processor of cannabis, based in Mission, BC and EFX labs, a medical products production and clinical research company based out of Calgary, AB.

Viridium is invested in a portfolio of products including a full spectrum of consumer needs, including products for Adult use, wellness and therapeutic daily use.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

For further information:

Viridium Pacific Group Ltd.
Jarrett Malnarich
Tel: (604) 837-8688
info@viridiumpacific.com

 

Disclosure      

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.

, , , , , , , , , , , , , , , ,

Stand for Something

Subscribe to our newsletter for updates
and curated content delivered to: